Spero Therapeutics, Inc. Operating Cash Flow
Spero Therapeutics, Inc. (SPRO) reported Operating Cash Flow of $10.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$5.36M.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $15.86M.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$8.35M.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $17.42M, a 36.50% increase year-over-year.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$12.62M.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$23.44M.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$32.99M.
- Spero Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$7.73M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $10.51M 10-Q · filed 2026-08-12 | $2.16M derived: sum of 3 quarters · filed 2026-08-12 | $19.58M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $15.86M 10-Q · filed 2026-05-13 | $7.51M derived: sum of 2 quarters · filed 2026-05-13 | $24.93M derived: sum of 3 quarters · filed 2026-05-13 | $7.24M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$8.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $9.07M derived: sum of 2 quarters · filed 2026-03-26 | -$8.62M derived: sum of 3 quarters · filed 2026-08-12 | -$12.62M 10-K · filed 2026-03-26 |
| 2025-09-30 | $17.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$271.00K derived: sum of 2 quarters · filed 2026-08-12 | -$4.27M 10-Q · filed 2025-11-13 | -$27.67M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$17.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$21.70M 10-Q · filed 2026-08-12 | -$45.10M derived: sum of 3 quarters · filed 2026-08-12 | -$32.33M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$4.00M 10-Q · filed 2026-05-13 | -$27.40M derived: sum of 2 quarters · filed 2026-05-13 | -$14.64M derived: sum of 3 quarters · filed 2026-05-13 | -$33.38M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$23.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$10.64M derived: sum of 2 quarters · filed 2026-03-26 | -$29.38M derived: sum of 3 quarters · filed 2026-03-26 | -$23.44M 10-K · filed 2026-03-26 |
| 2024-09-30 | $12.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$5.98M derived: sum of 2 quarters · filed 2025-11-13 | -$43.00K 10-Q · filed 2025-11-13 | -$17.54M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$18.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$12.81M 10-Q · filed 2025-08-12 | -$30.30M derived: sum of 3 quarters · filed 2025-08-12 | -$14.38M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $5.94M 10-Q · filed 2025-05-13 | -$11.55M derived: sum of 2 quarters · filed 2025-05-13 | $4.36M derived: sum of 3 quarters · filed 2025-05-13 | -$14.20M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$17.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$1.58M derived: sum of 2 quarters · filed 2025-03-27 | -$20.14M derived: sum of 3 quarters · filed 2025-03-27 | -$32.99M 10-K · filed 2025-03-27 |
| 2023-09-30 | $15.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$2.65M derived: sum of 2 quarters · filed 2024-11-14 | -$15.50M 10-Q · filed 2024-11-14 | $28.98M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$18.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$31.42M 10-Q · filed 2024-08-05 | $13.06M derived: sum of 3 quarters · filed 2024-08-05 | $12.11M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | -$12.85M 10-Q · filed 2024-05-15 | $31.63M derived: sum of 2 quarters · filed 2024-05-15 | $30.67M derived: sum of 3 quarters · filed 2024-05-15 | $7.64M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $44.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $43.52M derived: sum of 2 quarters · filed 2024-03-13 | $20.49M derived: sum of 3 quarters · filed 2024-03-13 | -$7.73M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$957.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$23.99M derived: sum of 2 quarters · filed 2023-11-13 | -$52.21M 10-Q · filed 2023-11-13 | -$79.56M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$23.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$51.26M 10-Q · filed 2023-08-10 | -$78.61M derived: sum of 3 quarters · filed 2023-08-10 | -$83.56M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$28.22M 10-Q · filed 2023-05-11 | -$55.57M derived: sum of 2 quarters · filed 2023-05-11 | -$60.52M derived: sum of 3 quarters · filed 2023-05-11 | -$77.09M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$27.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$32.30M derived: sum of 2 quarters · filed 2023-03-30 | -$48.87M derived: sum of 3 quarters · filed 2023-03-30 | -$64.35M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$4.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$21.52M derived: sum of 2 quarters · filed 2022-11-14 | -$37.00M 10-Q · filed 2022-11-14 | -$53.38M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$16.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$32.05M 10-Q · filed 2022-08-10 | -$48.43M derived: sum of 3 quarters · filed 2022-08-10 | -$69.69M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$15.48M 10-Q · filed 2022-05-16 | -$31.86M derived: sum of 2 quarters · filed 2022-05-16 | -$53.13M derived: sum of 3 quarters · filed 2022-05-16 | -$78.02M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$16.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$37.65M derived: sum of 2 quarters · filed 2022-03-31 | -$62.54M derived: sum of 3 quarters · filed 2022-03-31 | -$85.87M 10-K · filed 2022-03-31 |
| 2020-09-30 | -$21.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$46.16M derived: sum of 2 quarters · filed 2021-11-10 | -$69.49M 10-Q · filed 2021-11-10 | -$86.86M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$24.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$48.23M 10-Q · filed 2021-08-05 | -$65.59M derived: sum of 3 quarters · filed 2021-08-05 | -$75.25M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$23.33M 10-Q · filed 2021-05-06 | -$40.70M derived: sum of 2 quarters · filed 2021-05-06 | -$50.35M derived: sum of 3 quarters · filed 2021-05-06 | -$62.42M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$17.37M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$27.03M derived: sum of 2 quarters · filed 2021-03-11 | -$39.10M derived: sum of 3 quarters · filed 2021-03-11 | -$50.02M 10-K · filed 2021-03-11 |
| 2019-09-30 | -$9.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$21.73M derived: sum of 2 quarters · filed 2020-11-05 | -$32.65M 10-Q · filed 2020-11-05 | -$46.16M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$12.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$22.99M 10-Q · filed 2020-08-06 | -$36.50M derived: sum of 3 quarters · filed 2020-08-06 | -$42.02M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | -$10.92M 10-Q · filed 2020-05-08 | -$24.43M derived: sum of 2 quarters · filed 2020-05-08 | -$29.95M derived: sum of 3 quarters · filed 2020-05-08 | -$38.59M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | -$13.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$19.02M derived: sum of 2 quarters · filed 2020-03-16 | -$27.66M derived: sum of 3 quarters · filed 2020-03-16 | -$39.63M 10-K · filed 2020-03-16 |
| 2018-09-30 | -$5.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$14.15M derived: sum of 2 quarters · filed 2019-11-04 | -$26.12M 10-Q · filed 2019-11-04 | -$38.86M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | -$8.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$20.60M 10-Q · filed 2019-08-08 | -$33.34M derived: sum of 3 quarters · filed 2019-08-08 | -$43.86M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | -$11.96M 10-Q · filed 2019-05-09 | -$24.70M derived: sum of 2 quarters · filed 2019-05-09 | -$35.22M derived: sum of 3 quarters · filed 2019-05-09 | |
| 2017-12-31 | -$12.74M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$23.25M derived: sum of 2 quarters · filed 2019-03-14 | -$39.11M 10-K · filed 2019-03-14 | |
| 2017-09-30 | -$10.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$26.37M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$15.86M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | -$28.96M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |